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INTRODUCTION
Chronic myeloid leukemia (CML) is characterized by the presence of an aberrant gene, BCR-ABL1, which encodes for a constitutively activated tyrosine kinase 1 .
The prognosis of patients with newly diagnosed CML has been dramatically improved with the development of agents targeting the BCR-ABL1 derived protein, i.e. tyrosine kinase inhibitors (TKIs).
The pivotal International Randomized Study of Interferon and STI571 (IRIS)
established imatinib as first-line treatment in chronic phase (CP) CML 2 . It showed that 69% of patients given frontline imatinib treatment achieved complete cytogenetic response (CCyR) after 12 months of treatment with 57%
of them also achieving a major molecular response (MMR). However, 7.9%
progressed to accelerated phase (AP) or blastic crisis (BC). 2, 3 At 8 years, the event-free survival (EFS) ( defined as time until the first occurrence of any of the following: death from any cause, progression to AP/BC, loss of a complete hematologic response or major cytogenetic response, or an increasing white cell count to > 20 x 10 9 /L) and projected overall survival (OS) were 81% and 85%, respectively. 4 Despite the excellent results obtained in the IRIS trial, 40% to 45% of patients discontinue imatinib for various reasons. These include also unsatisfactory therapeutic outcomes in 16% of patients defined as failure to achieve response by a specific time point (namely, complete hematological response
[CHR] at 3 months or primary resistance) or the loss of initial response (e.g., loss of CCyR or secondary resistance) 5 .
In addition, the results for high risk CP-CML patients, based on prognostic scoring models 6, 7 are less favorable, with estimated EFS of 67.3% compared to 90.8% for the low risk patients. 8 Second generation TKIs include nilotinib, dasatinib and bosutinib. Similar to imatinib, nilotinib binds an inactive conformation of BCR-ABL1, with a 30 to 50 fold increased binding affinity 9 . Dasatinib binds to a distinct, although overlapping, binding site within the ATP-binding pocket and is 325-fold more potent than imatinib 10 . Bosutinib binds to a conformation of ABL1 that is transitional between the active and inactive conformations and is about 25-fold more potent than imatinib in vitro 11 . Phase 2 clinical trials showed advantage of second generation TKIs when used as second line treatment in patients with CP-CML 12 . These results, in patients failing or intolerant to imatinib, encouraged investigators to assess their role as first-line treatment in newly diagnosed CML patients. In prospective non-randomized phase 2 trials, these newer agents showed both earlier and higher rates of cytogenetic and molecular responses 13, 14 . These positive results led to the initiation of randomized controlled trials aiming to evaluate response rate and long-term outcomes of second generation TKIs in comparison to imatinib as first-line treatment in patients with CP-CML [15] [16] [17] [18] [19] .
The aim of this systematic review and meta-analysis is to evaluate the efficacy and safety of second generation TKIs as compared to imatinib for first-line treatment in CP-CML patients.
DESIGN AND METHODS

Data sources
We searched PubMed (January 1966 to July 2011), the Cochrane Central 20 We scanned the references of all included studies and reviews identified for additional trials that did not come up in our search.
Inclusion criteria
We included all randomized controlled trials comparing second and third generation TKIs to imatinib as first-line treatment for newly diagnosed, previously untreated (except for treatment with hydroxyurea or anagrelide), CP-CML patients. The diagnosis of CML in the trials was based on cytogenetic and/or FISH and/or RT-PCR results. Patients were included irrespective of age or of risk based on prognostic score methods 6, 7 .
We included trials regardless of publication status, date of publication and language. One author (RG) screened all references identified through our search strategy and references which could potentially fulfill inclusion criteria were drawn for further inspection. Two reviewers (RG, AG) independently inspected each of these abstracts and applied inclusion criteria. For possibly relevant articles or in the event of disagreement between the two reviewers, we obtained and independently inspected the full article.
Data extraction and risk of bias assessment
Two reviewers independently extracted data from included trials. In the event of disagreement between the two reviewers (RG, AG), a third reviewer (LV)
extracted the data and results were attained by consensus. We contacted the authors of trials for missing data when necessary. The risk of bias of included trials was independently appraised by two reviewers (RG, AG). We individually assessed the following domains: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data reporting, selective outcome reporting. We made critical assessment separately for each domain and graded it as low risk for bias, unclear risk, or high risk for bias according to the criteria specified in the Cochrane Handbook version 5.1.0 21 .
Definition of outcomes
For the primary outcome, we chose both CCyR and MMR at 12 months. 
Data synthesis and analysis
For each trial, results were expressed as relative risks (RR) with 95% confidence intervals (CI) for dichotomous data.
We assessed heterogeneity using the I 2 measure of inconsistency, which is more sensitive than the chi-square test for detecting heterogeneity in a metaanalysis with a small number of trials. See further explanations on assessing heterogeneity in the Online Supplementary Appendix.
We conducted meta-analysis using a fixed-effect model, which assumes a similar effect measure between studies and is appropriate when no significant clinical and statistical heterogeneity is present 20,22 (Further details regarding this method are described in the Online Supplementary Appendix).
For CCyR and MMR, RR>1 was in favor of the newer TKIs group. For progression to AP/BC, all-cause mortality, CML-related mortality and toxicity, RR<1 was in favor of the newer TKIs group.
For primary outcomes, we conducted an intention to treat (ITT) analysis, according to allocated treatment, and a per protocol analysis as a sensitivity analysis. In an ITT analysis each randomized patient is accounted for and analyzed in the allocated group (whether the patient received the treatment or not) whereas per protocol analysis includes only patients who actually received the therapy and were followed with surveillance cytogenetic and Figure 3 ).
Secondary Outcomes
Compared to imatinib, treatment with second generation TKIs significantly improved CCyR rates at 18 months but not at 24 months, with a RR of 1.09
(95% CI 1.03 to 1.14, I 2 =53%, 1867 patients) and 1.04 (95% CI 0.99 to 1.09, There was no statistically significant difference between the two allocated groups in all-cause mortality rates at 12, 18 and 24 months: RR 0.76 (95% CI deaths), respectively ( Figure 5 ). The rate of CML-related mortality at the end follow up (ranging between 12 to 24 months) was statistically significantly lower with the use of the newer TKIs as compared to imatinib (RR 0.58, 95%
CI 0.34 to 0.98, I 2 =0%, 2113 patients). Assuming 2% CML-related mortality rate in the control arm (imatinib), we calculated a NNT of 100 (95% CI 33 to 1000), meaning 100 patients need to be treated in order to prevent one CMLrelated death.
Safety analysis
We could not perform a meta-analysis comparing adverse events between imatinib and the second generation months. This might be attributed to the single trial comparing bosutinib to imatinib, probably, due to a high dropout rate in the bosutinib arm 15 .
Alternatively, this lack of difference at 24 months might be true and a longer follow up is warranted to solve this issue.
Although individual studies have shown higher rates of complete molecular response (CMR) with 2 nd generation TKIs compared to imatinib, we did not have enough data to compare the depth of response between the two investigated groups. CMR could serve as a forerunner for "cure" and as a parameter allowing for TKI cessation. Interestingly, one study which applied a highly sensitive patient-specific nested quantitative PCR analyzing genomic DNA provided evidence that even patients who maintained a CMR once after stopping imatinib may harbor residual leukemia. Taken together, it is suggested that CMR and/or methods using genomic DNA analysis to monitor residual disease might serve in the future as a surrogate for clinical endpoints such as overall survival 32 .
The present meta-analysis showed a statistically significant advantage in terms of CCyR in favor of the newer TKIs also in patients with high risk CML.
Since according to the IRIS trial, the risk of progression to AP/BC at 5 years is higher in this risk group as compared to the low risk group (17% vs. 3%, respectively,), this finding might have practical implications for these patients 29 .
A notable result is the fact that progression to advanced stages (AP and BC)
was halted by the newer TKIs with a NNT of 33. This is very significant in view of the dismal prognosis of patients developing these stages, even in the era of either directly to nilotinib or to higher imatinib doses and if then not achieving molecular targets, to nilotinib in the TIDEL II study 39 . Results from these trials showed that the TIDEL-II strategy using nilotinib has achieved a higher rate of MMR at 12 months compared to the strategy of imatinib intensification used in the TIDEL-I study.
Our meta-analysis has several limitations. The first one is the paucity of trials included and the limited sample size which did not allow for the assessment of differences in overall survival, the most important outcome. Moderate heterogeneity was detected in most analyses. However, nearly all studies showed the same trend, thus heterogeneity stemmed from different magnitudes of the same effect and not from different directions of effects.
Another limitation is the short term follow-up of the trials included, which might be responsible for the lack of difference in survival between the two arms, especially in view of the longevity of CML in the imatinib era 8 
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